Skip to main content

Incretins and incretin-based therapies for obesity, diabetes and other metabolic disorders

Guest Editors:
Nicolai Wewer Albrechtsen, MD, PhD: Department of Clinical Biochemistry, Copenhagen University Hospital – Bispebjerg, Copenhagen, Denmark
Flávio Adsuara Cadegiani, MD, MSc, PhD: Corpometria Institute, Brasilia, Brazil
Victor Gault, PhD: Ulster University, Northern Ireland, United Kingdom

Gastric inhibitory polypeptide (GIP)BMC Endocrine Disorders called for submissions to our Collection on Incretins and incretin-based therapies for obesity, diabetes and other metabolic disorders.

We encouraged submission of articles providing (or summarizing) new insights on topics ranging from the elucidation of molecular mechanisms of incretins in homeostasis and disease to the description of novel treatments based on incretin agonists, co-agonists and poly-agonists for obesity, diabetes and other metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Articles describing original research, or studies with translational potential, as well as pre-clinical and clinical investigations are all welcome.

New Content ItemThis Collection supports and amplifies research related to SDG 3: Good Health and Well-Being.

Meet the Guest Editors

Back to top

Nicolai Wewer Albrechtsen, MD, PhD: Department of Clinical Biochemistry, Copenhagen University Hospital – Bispebjerg, Copenhagen, Denmark

Dr Wewer Albrechtsen is a consultant and Associate Professor and has worked for more than 10 years in the field of glucagon-like peptides, in particular their relevance to metabolic diseases. He was trained by Prof Jens Juul Holst and has since developed his own laboratory, in which he and his group focus on translational hormonal research in the context of diabetes, obesity and NAFLD. Dr Wewer Albrechtsen is interested in the pathophysiological and clinical implications of glucagon-like peptides, how to measure them accurately, how they appear to have multiorgan effects and how they signal through G-protein Coupled Receptors.
 

Flávio Adsuara Cadegiani, MD, MSc, PhD: Corpometria Institute, Brasilia, Brazil

Dr Flavio Cadegiani is a board-certified endocrinologist with PhD in Clinical Endocrinology at Federal University of São Paulo. Focused on the use of GLP-1 analogues alone or combination with other drug classes and publication of the results of his center. 


 

Victor Gault, PhD: Ulster University, Northern Ireland, United Kingdom

Professor Victor Gault is currently Professor of Experimental Medicine and Associate Dean for Research and Innovation at Ulster University. He studied biochemistry at Queen’s University Belfast and obtained his PhD in diabetes and endocrinology from Ulster University. His research interests focus on the biochemical and physiological function of gut-derived hormones and bioengineered forms in healthy and diseased states, with particular emphasis on the potential role of gut peptides in the treatment of diabetes, obesity and associated neurodegenerative disorders. Professor Gault is the holder of international patents/patent families for novel diabetes therapeutics and is a member of several professional societies, national and international committees, and Editorial Boards.

About the Collection

Gastric inhibitory polypeptide (GIP)BMC Endocrine Disorders called for submissions to our Collection on Incretins and incretin-based treatments for obesity, diabetes and other metabolic disorders to cover the multiple facets of the recently described and still not fully explored incretin system.

Potential topics of interest for this Collection include, but are not limited to:

  • Mechanisms of action of incretin hormones
  • Role of incretins in metabolic homeostasis and disease pathophysiology
  • Established and emerging incretin-based therapies and targets
  • Clinical efficacy and safety
  • Long-term outcomes, surveillance, and sustainability

This Collection of research articles contributes to Sustainable Development Goal 3: Good Health and Well-Being. By advancing our understanding of incretin biology and the development of effective treatments for diabetes, obesity, MASLD and MASH this research aligns with efforts to promote healthier lives and enhance healthcare access.

Image credit: molekuul.be /Stock.adobe.com

  2. Glucagon is secreted from pancreatic alpha cells in response to low blood glucose and increases hepatic glucose production. Furthermore, glucagon enhances hepatic protein and lipid metabolism during a mixed me...

    Authors: Dorte B. Zilstorff, Michael M. Richter, Jens Hannibal, Henrik L. Jørgensen, Henriette P. Sennels and Nicolai J. Wewer Albrechtsen
    Citation: BMC Endocrine Disorders 2024 24:38
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection. To choose this collection, please select Incretins and incretin-based treatments for diabetes and obesity from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.